Connection

Maria Lopes-Virella to Male

Back to Details
This is a "connection" page, showing publications Maria Lopes-Virella has written about Male.
Maria Lopes-Virella
Connection Strength
0.654
Male
  1. Immune Complexes and the Risk of CVD in Type 1 Diabetes. Diabetes. 2019 09; 68(9):1853-1860.
    View in: PubMed
    Score: 0.035
  2. Glycosylated sphingolipids and progression to kidney dysfunction in type 1 diabetes. J Clin Lipidol. 2019 May - Jun; 13(3):481-491.e1.
    View in: PubMed
    Score: 0.035
  3. High levels of AGE-LDL, and of IgG antibodies reacting with MDA-lysine epitopes expressed by oxLDL and MDA-LDL in circulating immune complexes predict macroalbuminuria in patients with type 2 diabetes. J Diabetes Complications. 2016 May-Jun; 30(4):693-9.
    View in: PubMed
    Score: 0.028
  4. Response to comment on Lopes-Virella et al. Baseline markers of inflammation are associated with progression to macroalbuminuria in type 1 diabetic subjects. Diabetes care 2013;36:2317-2323. Diabetes Care. 2014 May; 37(5):e108-9.
    View in: PubMed
    Score: 0.024
  5. Baseline markers of inflammation are associated with progression to macroalbuminuria in type 1 diabetic subjects. Diabetes Care. 2013 Aug; 36(8):2317-23.
    View in: PubMed
    Score: 0.023
  6. The levels of MDA-LDL in circulating immune complexes predict myocardial infarction in the VADT study. Atherosclerosis. 2012 Oct; 224(2):526-31.
    View in: PubMed
    Score: 0.022
  7. Levels of oxidized LDL and advanced glycation end products-modified LDL in circulating immune complexes are strongly associated with increased levels of carotid intima-media thickness and its progression in type 1 diabetes. Diabetes. 2011 Feb; 60(2):582-9.
    View in: PubMed
    Score: 0.019
  8. Risk factors related to inflammation and endothelial dysfunction in the DCCT/EDIC cohort and their relationship with nephropathy and macrovascular complications. Diabetes Care. 2008 Oct; 31(10):2006-12.
    View in: PubMed
    Score: 0.017
  9. Role of simvastatin as an immunomodulator in type 2 diabetes. Diabetes Care. 2004 Apr; 27(4):908-13.
    View in: PubMed
    Score: 0.012
  10. Serum urate and cardiovascular events in the DCCT/EDIC study. Sci Rep. 2021 07 09; 11(1):14182.
    View in: PubMed
    Score: 0.010
  11. Rationale, Design, and Implementation of Intensive Risk Factor Treatment in the CREST2 Trial. Stroke. 2020 10; 51(10):2960-2971.
    View in: PubMed
    Score: 0.010
  12. Longitudinal Plasma Kallikrein Levels and Their Association With the Risk of Cardiovascular Disease Outcomes in Type 1 Diabetes in DCCT/EDIC. Diabetes. 2020 11; 69(11):2440-2445.
    View in: PubMed
    Score: 0.010
  13. Anti-modified LDL antibodies, LDL-containing immune complexes, and susceptibility of LDL to in vitro oxidation in patients with type 2 diabetes. Diabetes. 2000 Jun; 49(6):1033-41.
    View in: PubMed
    Score: 0.009
  14. Risk Factors for Diabetic Peripheral Neuropathy and Cardiovascular Autonomic Neuropathy in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study. Diabetes. 2020 05; 69(5):1000-1010.
    View in: PubMed
    Score: 0.009
  15. Risk Factors for First and Subsequent CVD Events in Type 1 Diabetes: The DCCT/EDIC Study. Diabetes Care. 2020 04; 43(4):867-874.
    View in: PubMed
    Score: 0.009
  16. Amitriptyline inhibits nonalcoholic steatohepatitis and atherosclerosis induced by high-fat diet and LPS through modulation of sphingolipid metabolism. Am J Physiol Endocrinol Metab. 2020 02 01; 318(2):E131-E144.
    View in: PubMed
    Score: 0.009
  17. Serum pigment epithelium-derived factor: Relationships with cardiovascular events, renal dysfunction, and mortality in the Veterans Affairs Diabetes Trial (VADT) cohort. J Diabetes Complications. 2019 10; 33(10):107410.
    View in: PubMed
    Score: 0.009
  18. Serum apolipoproteins and apolipoprotein-defined lipoprotein subclasses: a hypothesis-generating prospective study of cardiovascular events in T1D. J Lipid Res. 2019 08; 60(8):1432-1439.
    View in: PubMed
    Score: 0.009
  19. Plasma levels of TNF-a, IL-6, IFN-?, IL-12, IL-17, IL-22, and IL-23 in achalasia, eosinophilic esophagitis (EoE), and gastroesophageal reflux disease (GERD). BMC Gastroenterol. 2019 Feb 11; 19(1):28.
    View in: PubMed
    Score: 0.009
  20. Antibodies to oxidized LDL and LDL-containing immune complexes as risk factors for coronary artery disease in diabetes mellitus. Clin Immunol. 1999 Feb; 90(2):165-72.
    View in: PubMed
    Score: 0.009
  21. Association of apolipoprotein A phenotypes and oxidized low-density lipoprotein immune complexes in children. Arch Pediatr Adolesc Med. 1999 Jan; 153(1):57-62.
    View in: PubMed
    Score: 0.009
  22. Late adulthood mortality among African-American and white American people with Type 1 diabetes according to age at diabetes diagnosis. Diabet Med. 2018 06; 35(6):729-736.
    View in: PubMed
    Score: 0.008
  23. Apolipoprotein-defined lipoprotein subclasses, serum apolipoproteins, and carotid intima-media thickness in T1D. J Lipid Res. 2018 05; 59(5):872-883.
    View in: PubMed
    Score: 0.008
  24. Plasma Connective Tissue Growth Factor (CTGF/CCN2) Levels Predict Myocardial Infarction in the Veterans Affairs Diabetes Trial (VADT) Cohort. Diabetes Care. 2018 04; 41(4):840-846.
    View in: PubMed
    Score: 0.008
  25. Association Between Inflammatory Markers and Progression to Kidney Dysfunction: Examining Different Assessment Windows in Patients With Type 1 Diabetes. Diabetes Care. 2018 01; 41(1):128-135.
    View in: PubMed
    Score: 0.008
  26. Anti-modified LDL antibodies and LDL-containing immune complexes in IDDM patients and healthy controls. Clin Immunol Immunopathol. 1997 Oct; 85(1):73-82.
    View in: PubMed
    Score: 0.008
  27. Cooperative stimulation of atherogenesis by lipopolysaccharide and?palmitic acid-rich high fat diet in low-density lipoprotein receptor-deficient mice. Atherosclerosis. 2017 10; 265:231-241.
    View in: PubMed
    Score: 0.008
  28. CD36 is upregulated in mice with periodontitis and metabolic syndrome and involved in macrophage gene upregulation by palmitate. Oral Dis. 2017 Mar; 23(2):210-218.
    View in: PubMed
    Score: 0.007
  29. Haptoglobin 2-2 genotype and the risk of coronary artery disease in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study (DCCT/EDIC). J Diabetes Complications. 2016 Nov - Dec; 30(8):1577-1584.
    View in: PubMed
    Score: 0.007
  30. F(ab')2 fragments of anti-oxidized LDL IgG attenuate vascular inflammation and atherogenesis in diabetic LDL receptor-deficient mice. Clin Immunol. 2016 Dec; 173:50-56.
    View in: PubMed
    Score: 0.007
  31. Increased Plasma Levels of Select Deoxy-ceramide and Ceramide Species are Associated with Increased Odds of Diabetic Neuropathy in Type 1 Diabetes: A Pilot Study. Neuromolecular Med. 2017 Mar; 19(1):46-56.
    View in: PubMed
    Score: 0.007
  32. LDL from patients with well-controlled IDDM is not more susceptible to in vitro oxidation. Diabetes. 1996 Jun; 45(6):762-7.
    View in: PubMed
    Score: 0.007
  33. Isolation and characterization of human antioxidized LDL autoantibodies. Arterioscler Thromb Vasc Biol. 1996 Feb; 16(2):222-9.
    View in: PubMed
    Score: 0.007
  34. Associations between intensive diabetes therapy and NMR-determined lipoprotein subclass profiles in type 1 diabetes. J Lipid Res. 2016 Feb; 57(2):310-7.
    View in: PubMed
    Score: 0.007
  35. Plasma Prekallikrein Is Associated With Carotid Intima-Media Thickness in Type 1 Diabetes. Diabetes. 2016 Feb; 65(2):498-502.
    View in: PubMed
    Score: 0.007
  36. Nuclear magnetic resonance-determined lipoprotein subclasses and carotid intima-media thickness in type 1 diabetes. Atherosclerosis. 2016 Jan; 244:93-100.
    View in: PubMed
    Score: 0.007
  37. Isolation, characterization, and metabolism of the glycated and nonglycated subfractions of low-density lipoproteins isolated from type I diabetic patients and nondiabetic subjects. Diabetes. 1995 Sep; 44(9):1093-8.
    View in: PubMed
    Score: 0.007
  38. TLR4 antagonist attenuates atherogenesis in LDL receptor-deficient mice with diet-induced type 2 diabetes. Immunobiology. 2015 Nov; 220(11):1246-54.
    View in: PubMed
    Score: 0.007
  39. Longitudinal Association Between Endothelial Dysfunction, Inflammation, and Clotting Biomarkers With Subclinical Atherosclerosis in Type 1 Diabetes: An Evaluation of the DCCT/EDIC Cohort. Diabetes Care. 2015 Jul; 38(7):1281-9.
    View in: PubMed
    Score: 0.007
  40. Metabolic syndrome exacerbates inflammation and bone loss in periodontitis. J Dent Res. 2015 Feb; 94(2):362-70.
    View in: PubMed
    Score: 0.006
  41. The predictive role of markers of Inflammation and endothelial dysfunction on the course of diabetic retinopathy in type 1 diabetes. J Diabetes Complications. 2015 Jan-Feb; 29(1):108-14.
    View in: PubMed
    Score: 0.006
  42. Plasma total homocysteine and carotid intima-media thickness in type 1 diabetes: a prospective study. Atherosclerosis. 2014 Sep; 236(1):188-195.
    View in: PubMed
    Score: 0.006
  43. Decreased plasma levels of select very long chain ceramide species are associated with the development of nephropathy in type 1 diabetes. Metabolism. 2014 Oct; 63(10):1287-95.
    View in: PubMed
    Score: 0.006
  44. Clinical correlates of serum pigment epithelium-derived factor in type 2 diabetes patients. J Diabetes Complications. 2014 May-Jun; 28(3):353-9.
    View in: PubMed
    Score: 0.006
  45. Oxidized LDL and AGE-LDL in circulating immune complexes strongly predict progression of carotid artery IMT in type 1 diabetes. Atherosclerosis. 2013 Dec; 231(2):315-22.
    View in: PubMed
    Score: 0.006
  46. Apolipoprotein-defined and NMR lipoprotein subclasses in the veterans affairs diabetes trial. J Diabetes Complications. 2013 Nov-Dec; 27(6):627-32.
    View in: PubMed
    Score: 0.006
  47. Apolipoprotein-defined lipoproteins and apolipoproteins: associations with abnormal albuminuria in type 1 diabetes in the diabetes control and complications trial/epidemiology of diabetes interventions and complications cohort. J Diabetes Complications. 2013 Sep-Oct; 27(5):447-53.
    View in: PubMed
    Score: 0.006
  48. Urine haptoglobin levels predict early renal functional decline in patients with type 2 diabetes. Kidney Int. 2013 Jun; 83(6):1136-43.
    View in: PubMed
    Score: 0.006
  49. Metabolism by human endothelial cells of very low density lipoprotein subfractions isolated from type 1 (insulin-dependent) diabetic patients. Diabetologia. 1993 Mar; 36(3):258-64.
    View in: PubMed
    Score: 0.006
  50. Influence of glycemic control on interaction of very-low- and low-density lipoproteins isolated from type I diabetic patients with human monocyte-derived macrophages. Diabetes. 1992 Oct; 41(10):1301-7.
    View in: PubMed
    Score: 0.006
  51. High concentrations of AGE-LDL and oxidized LDL in circulating immune complexes are associated with progression of retinopathy in type 1 diabetes. Diabetes Care. 2012 Jun; 35(6):1333-40.
    View in: PubMed
    Score: 0.005
  52. Immunosuppressive effects of fish oil in normal human volunteers: correlation with the in vitro effects of eicosapentanoic acid on human lymphocytes. Clin Immunol Immunopathol. 1991 Nov; 61(2 Pt 1):161-76.
    View in: PubMed
    Score: 0.005
  53. High levels of oxidized LDL in circulating immune complexes are associated with increased odds of developing abnormal albuminuria in Type 1 diabetes. Nephrol Dial Transplant. 2012 Apr; 27(4):1416-23.
    View in: PubMed
    Score: 0.005
  54. DPP-4 (CD26) inhibitor alogliptin inhibits atherosclerosis in diabetic apolipoprotein E-deficient mice. J Cardiovasc Pharmacol. 2011 Aug; 58(2):157-66.
    View in: PubMed
    Score: 0.005
  55. Insulin treatment attenuates diabetes-increased atherosclerotic intimal lesions and matrix metalloproteinase 9 expression in apolipoprotein E-deficient mice. J Endocrinol. 2011 Jul; 210(1):37-46.
    View in: PubMed
    Score: 0.005
  56. Analyses of renal outcome following transplantation adjusting for informative right censoring and demographic factors: A longitudinal study. Ren Fail. 2010 Jul; 32(6):691-8.
    View in: PubMed
    Score: 0.005
  57. LDL-containing immune complexes in the DCCT/EDIC cohort: associations with lipoprotein subclasses. J Diabetes Complications. 2011 Mar-Apr; 25(2):73-82.
    View in: PubMed
    Score: 0.005
  58. Genetic variant in the promoter of connective tissue growth factor gene confers susceptibility to nephropathy in type 1 diabetes. J Med Genet. 2010 Jun; 47(6):391-7.
    View in: PubMed
    Score: 0.005
  59. Metabolism of very low- and low-density lipoproteins isolated from normolipidaemic type 2 (non-insulin-dependent) diabetic patients by human monocyte-derived macrophages. Diabetologia. 1990 May; 33(5):299-305.
    View in: PubMed
    Score: 0.005
  60. Genome-wide association identifies the ABO blood group as a major locus associated with serum levels of soluble E-selectin. Arterioscler Thromb Vasc Biol. 2009 Nov; 29(11):1958-67.
    View in: PubMed
    Score: 0.004
  61. Periodontal disease status in gullah african americans with type 2 diabetes living in South Carolina. J Periodontol. 2009 Jul; 80(7):1062-8.
    View in: PubMed
    Score: 0.004
  62. Effects of magnesium oxide on the lipid profile of healthy volunteers. Atherosclerosis. 1989 May; 77(1):37-42.
    View in: PubMed
    Score: 0.004
  63. Enhancement of platelet aggregation by low-density lipoproteins from IDDM patients. Diabetes. 1988 Dec; 37(12):1652-7.
    View in: PubMed
    Score: 0.004
  64. A trend of increase in periodontal interleukin-6 expression across patients with neither diabetes nor periodontal disease, patients with periodontal disease alone, and patients with both diseases. J Periodontal Res. 2008 Dec; 43(6):717-22.
    View in: PubMed
    Score: 0.004
  65. Connective tissue growth factor and susceptibility to renal and vascular disease risk in type 1 diabetes. J Clin Endocrinol Metab. 2008 May; 93(5):1893-900.
    View in: PubMed
    Score: 0.004
  66. Stimulation of cholesteryl ester synthesis in human monocyte-derived macrophages by low-density lipoproteins from type 1 (insulin-dependent) diabetic patients: the influence of non-enzymatic glycosylation of low-density lipoproteins. Diabetologia. 1987 Dec; 30(12):916-23.
    View in: PubMed
    Score: 0.004
  67. Intensive treatment of diabetes is associated with a reduced rate of peripheral arterial calcification in the diabetes control and complications trial. Diabetes Care. 2007 Oct; 30(10):2646-8.
    View in: PubMed
    Score: 0.004
  68. Glycosylation of low density lipoprotein in patients with type 1 (insulin-dependent) diabetes: correlations with other parameters of glycaemic control. Diabetologia. 1986 Oct; 29(10):685-9.
    View in: PubMed
    Score: 0.004
  69. Nuclear magnetic resonance-determined lipoprotein subclass profile in the DCCT/EDIC cohort: associations with carotid intima-media thickness. Diabet Med. 2006 Sep; 23(9):955-66.
    View in: PubMed
    Score: 0.004
  70. Pioglitazone inhibits connective tissue growth factor expression in advanced atherosclerotic plaques in low-density lipoprotein receptor-deficient mice. Atherosclerosis. 2007 May; 192(1):85-91.
    View in: PubMed
    Score: 0.004
  71. Diabetic lipoprotein deficient serum: its effect in low density lipoprotein (LDL) uptake and degradation by fibroblasts. Metabolism. 1985 Dec; 34(12):1079-85.
    View in: PubMed
    Score: 0.003
  72. Novel predictors of overt nephropathy in subjects with type 1 diabetes. A nested case control study from the Pittsburgh Epidemiology of Diabetes Complications cohort. Nephrol Dial Transplant. 2006 Jan; 21(1):93-100.
    View in: PubMed
    Score: 0.003
  73. Markers of endothelial dysfunction in the prediction of coronary artery disease in type 1 diabetes. The Pittsburgh Epidemiology of Diabetes Complications Study. J Diabetes Complications. 2005 Jul-Aug; 19(4):183-93.
    View in: PubMed
    Score: 0.003
  74. The prospective association between adiponectin and coronary artery disease among individuals with type 1 diabetes. The Pittsburgh Epidemiology of Diabetes Complications Study. Diabetologia. 2005 Jan; 48(1):41-8.
    View in: PubMed
    Score: 0.003
  75. Effect of metabolic control on lipid, lipoprotein, and apolipoprotein levels in 55 insulin-dependent diabetic patients. A longitudinal study. Diabetes. 1983 Jan; 32(1):20-5.
    View in: PubMed
    Score: 0.003
  76. Proatherogenic and proinflammatory properties of immune complexes prepared with purified human oxLDL antibodies and human oxLDL. Clin Immunol. 2002 Oct; 105(1):81-92.
    View in: PubMed
    Score: 0.003
  77. Surface binding, internalization and degradation by cultured human fibroblasts of low density lipoproteins isolated from type 1 (insulin-dependent) diabetic patients: changes with metabolic control. Diabetologia. 1982 Jun; 22(6):430-6.
    View in: PubMed
    Score: 0.003
  78. Plasma lipids and lipoproteins in young insulin-dependent diabetic patients: relationship with control. Diabetologia. 1981 Sep; 21(3):216-23.
    View in: PubMed
    Score: 0.003
  79. Use of fenofibrate in the management of protease inhibitor-associated lipid abnormalities. Pharmacotherapy. 2000 Jun; 20(6):727-34.
    View in: PubMed
    Score: 0.002
  80. Urinary high density lipoprotein in minimal change glomerular disease and chronic glomerulopathies. Clin Chim Acta. 1979 May 16; 94(1):73-81.
    View in: PubMed
    Score: 0.002
  81. Early diagnosis of renal malfunction in diabetics. Abnormal proteinuria revealed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Diabetologia. 1979 Mar; 16(3):165-71.
    View in: PubMed
    Score: 0.002
  82. Serum high density lipoprotein in diabetic patients. Diabetologia. 1977 Aug; 13(4):285-91.
    View in: PubMed
    Score: 0.002
  83. Release of platelet plasminogen activator inhibitor 1 in whole blood is increased in patients with type II diabetes. Diabetes Care. 1995 Aug; 18(8):1150-5.
    View in: PubMed
    Score: 0.002
  84. Platelet plasminogen activator inhibitor 1 in patients with type II diabetes. Diabetes Care. 1994 Aug; 17(8):818-23.
    View in: PubMed
    Score: 0.002
  85. Platelet function during continuous insulin infusion treatment in insulin-dependent diabetic patients. Diabetes. 1985 Nov; 34(11):1127-33.
    View in: PubMed
    Score: 0.001
  86. Effect of insulin treatment in streptozocin-induced diabetic rats on in vitro platelet function and plasma von Willebrand factor activity and factor VIII-related antigen. J Lab Clin Med. 1985 Sep; 106(3):319-25.
    View in: PubMed
    Score: 0.001
  87. Time course of changes in in vitro platelet function and plasma von willebrand factor activity (VIIIR:WF) and factor VIII-related antigen (VIIIR:Ag) in the diabetic rat. J Lab Clin Med. 1983 Nov; 102(5):795-804.
    View in: PubMed
    Score: 0.001
  88. Decreased high density lipoprotein cholesterol in hypopituitarism. J Clin Endocrinol Metab. 1979 Nov; 49(5):753-6.
    View in: PubMed
    Score: 0.001
  89. "Idiopathic" Bence-Jones proteinuria. Acta Haematol. 1978; 60(5):269-79.
    View in: PubMed
    Score: 0.000
  90. Asynchronous development of two monoclonal proteins (IgM lambda and delta 1 chains) in a patient with abdominal lymphoma. Cancer. 1977 May; 39(5):2247-53.
    View in: PubMed
    Score: 0.000
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.